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Abstract

The temporomandibular disorders (TMD) etiology is multifactorial and it affects the most
important functions, such as eating, speaking, and facial expressions, and are usually accompanied
by pain which results in distress for the patient. Despite the extensive studies in the management
of TMD, which is commonly a multidisciplinary approach and the most commonly used steroidal
or nonsteroidal anti-inflammatory, myorelaxant, tricyclic antidepressants, anticonvulsants and
anxiolytics have been proven to be successful for related inflammatory, disc interference disorders
only and neuropathic pain, but are still not an appropriate solution for definitive treatments and
still carries risk due to their side effect profiles. Taking this into consideration there is still an
emerging need to investigate the main pharmacological approaches for the appropriate
management of the resulting acute and chronic pain. In this regard, many studies have been
conducted so far to provide the role of pharmacotherapy on TMD. Therefore, in this review, we
have summarized the current scientific evidence which supports the most common available safe,
and effective drug treatments in the TMD.
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Introduction

The temporomandibular disorders (TMD) etiology is multifactorial and it affects the most
important functions, such as eating, speaking, and facial expressions, and are usually accompanied
by pain which results in distress for the patient (1). TMDs induces pain, joint sounds, mandibular
movement problems or jaw function, malocclusion (2). TMD classification is shown in Table
1Patient with TMD experiences also headaches and sleep related problems, with a higher incidence
in women’s (3). Most common population, like 33% experience at least one TMD symptom,
however 3.6-7.0 % have a need for management (4). However, despite the extensive studies in the
management of TMD, it is usually considered as a multidisciplinary approach including nonpharmacologic and pharmacologic management. The most commonly used pharmacological
agents for the management of TMD symptoms, especially inflammation and pain are, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, muscle relaxants, opioids and other
central nervous agents such as anticonvulsants, antidepressant and anxiolytics (5). These agents
have been proven to be successful for related inflammatory, disc interference disorders only and
neuropathic pain, but are still not an appropriate solution for definitive treatments and still carries
risk due to their side effect profiles and reduced or unknown efficacy. Therefore in this mini
review, we have summarized their pharmacological actions and most common available
treatments, their safety and efficacy in management of TMD.

Table 1. TMD classification based on the diagnostic criteria (Modified from Peck CC et al., 2014)6
1 Masticatory Muscle
Disorders

1 Protective co-contraction
2 Local muscle soreness
3 Myofascial pain
4 Myospasm
5 Centrally mediated myalgia

2A Temporomandibular Joint
Disorders

1 Derangement of the condyle-disc complex
2. Disc displacements
3 Disc dislocation with reduction
Disc dislocation without reduction
1 Deviation in form
2 Disc
3 Condyle
4. Fossa
5 Adhesions
6 Disc to condyle

2B Structural incompatibility
of the articular surfaces

7 Disc to fossa
8 Subluxation (hypermobility)
9 Spontaneous dislocation

2C Inflamatory Disorders of
the TMJ

1 Synovitis/Capsulitis
1 Retrodiscitis
2 Arthritides
3 Osteoarthritis
4. Osteoarthrosis
5 Polyarthritides
6 Inflammatory disorders of associated structures
7 Temporalis tendonitis
8 Stylomandibular ligament inflammation

3. Chronic Mandibular
hypomobility

1. Ankylosis
2. Fibrous
3 Bony
4 Muscle contracture

4. Growth Disorders

5 Myostatic
6 Myofibrotic
7 Coronoid impedance
1 Congenital and developmental bone disorders
2 Agenesis
3 Hypoplasia
4 Hyperplasia
5 Neoplasia
6 Congenital and developmental muscle disorders
Hypotrophy
7 Hypertrophy
8 Hypertrophy
9. Neoplasia

2. Pharmacological Treatment of Temporomandibular Disorders

Pharmacologic therapy is needed for controlling inflammation, pain (acute or chronic), and muscle
spasm as main symptoms of TMD. The most common pharmacological treatment is usually
empirical and is divided into four different groups, including, anti-inflammatory drugs including
nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and systemic nervous system
action drugs such as muscle relaxants, opioids, anticonvulsants, antidepressants, anxiolytics, and
other target actions including hyaluronic acid and glucosamine and bioactive and traditional plants
(7).

2.1 NSAIDs

Based on their anti-inflammatory and analgesic pharmacological properties, NSAIDs are the firstline medication for the treatment of pain and inflammation in TMD, with a focus on disc
displacement, synovitis, arthritis, and capsulitis (8). These agents can be used also in the
management of pain from masticatory myalgia and myofascial pain (9). The most common
NSAIDs used are diclofenac, naproxen sodium, ibuprofen, celecoxib, piroxicam etc (10), and the
period of use for such indication consists of a minimal 2 week period, suggesting long-term
treatment to obtain the clinical effects (11). Despite their beneficial actions they possess
gastrointestinal, renal, and cardiovascular side effects (12). The most common gastrointestinal and
cardiovascular side effect is bleeding, ulceration, and risk for atherothrombosis, which alerts close
monitoring during the period of their use (13). Even though the gastrointestinal effects are
diminished with selective cyclooxygenase-2 inhibitors (COXIBs) they pave the road more for
cardiovascular-related side effects, which faded their clinical use perspective due to safety
concerns (14). They interfere with other drugs in increasing toxicity, including methotrexate,
lithium, and reduction of antihypertensive drug effects (diuretics and ACE inhibitors) and increase
anticoagulation effects (15). In addition to this NSAIDs are combined with derivates of paminophenol, such as acetaminophen or paracetamol to provide synergic effects in controlling
acute TMD pain (16).

2.2 Corticosteroids

Corticosteroids are potent anti-inflammatory drugs in the management of moderate to severe TMD
and are mainly administered as locally injected in the joints with intra-articular injections, topically
or orally (17). Their use needs to be limited for no more than a sustained two-week period due to
an increase of susceptibility for infections due to their immunosuppressive actions, hyperglycemia,
osteoporosis, suppression of hypothalamic-pituitary-adrenal axis, etc (18). In order to minimize
their side effects, they must be limited to a short period of use with a local intra-articular injection
(19). Therefore, methylprednisolone, triamcinolone acetonide, betamethasone, dexamethasone
alone or in combination with lidocaine, hyaluronic acid, and NSAIDs have been proven to improve
symptoms of TMD (20). However, due to their poor side effect profile, with a focus on
degenerative changes in joints, their use needs to be limited for every 3 to 4 months (21, 22).

2.3 Muscle Relaxants
Muscle relaxants reduce the skeletal muscle tone associated with higher masticatory and cervical
muscle contraction and are used in a patient with TMD related to chronic orofacial pain or musclerelated symptoms (23). This includes central muscle relaxants cyclobenzaprine (similar structure
to tricyclic antidepressants), carisoprodol, carisoprodolmetaxalone, methocarbamol, tizanidine,
diazepam, and peripheral such as baclofen, botulinum toxin A, dantrolene (24). Central muscle
relaxant use needs to be limited during the driving period and due to their sedative properties are
in preferred in the lowest dosage before sleeping, and also their anticholinergic side effect profile
need to be monitored (25). Their general use consists of a continuous 30 day period of use,
followed by 2 weeks as a washout period, and return for additional 2-3 months if necessary (9).
However, despite their meaningful clinical data, their long-term clinical use and efficacy are still
not clear (16). For example, botulinum toxin alone or combined use is not supported by the
currently available evidence in subacute and chronic pain (26).

2.4 Opioids

Opioids or narcotic analgesics are characterized and used for controlling more moderate to severe
pain from TMD, where the other drugs are found ineffective (27). These agents are recommended
to be limited to short-term and acute pain control, due to knowing the risk due to their side effect
profile such as respiratory depression, sedation, constipation, and the most common
pharmacological concerns regarding the tolerance and physical dependence caused by this agent
(28). Despite that these agents are not considered as first-line therapy for managing TMDassociated pain, the most commonly prescribed opioids in TMD are oral use of hydrocodone,
oxycodone, and codeine (4). However, fentanyl patches or intra-articular morphine injection can
be also be considered when the oral route is not a reasonable option (29). The prescription of this
agent should be carefully considered and limited due to special concerns of patients with substance
use disorders, with a major focus in the chronic course of therapy since there are no final
conclusions of long-term therapeutically benefits and due to tolerance and abusing tendency (30).

2.5 Central Nervous System Drug Agents

The central nervous drug agents used in TMD are anticonvulsants, antidepressants, and anxiolytics
these agents are used to control pain, gabapentin, pregabalin as an anticonvulsant are used to treat
pain and tenderness in masticatory muscles, with a focus in mainly neuropathic pain (31, 32). In
addition, antidepressant drugs as alone or in combination with anticonvulsants, including mainly
tricyclic antidepressants and serotonin-noradrenalin re-uptake inhibitors, serotonin selective reuptake inhibitors are used to manage TMD-related bruxism, muscle pain-related sleep disorders,
fibromyalgia, chronic pain in the orofacial region which might have depression or sleep as a
comorbid disease. The common use of antidepressant drugs in TMD are amitriptyline,
nortriptyline, desipramine, fluoxetine, paroxetine (33). These drugs need to be used with caution
in a patient with cardiovascular diseases and concomitant use with monoamine oxidase Inhibitors
(34). In the end, the anxiolytics include mainly benzodiazepines specifically: diazepam and
clonazepam. Drugs in the central nervous system need to be prescribed with caution from the
dental community and need to be in consultation with physicians to ensure their diagnosis, medical
stability, and management of the side effects (35).

3. Other Complementary Alternatives

Despite the current presence of approved pharmacological treatments in the management of TMD,
there are some complementary alternatives that are mainly empirical treatments without strong
evidence to support their effectiveness and that are being used nowadays, including hyaluronic
acid, glucosamine, and traditional agents (7, 36, 37). Hyaluronic acid is commonly used in
combination with glucocorticoids via intra-articular injection for the treatment of TMD.This
controls the myofascial pain within the masseter muscle, restores the viscoelasticity of synovial
fluid in the inflamed joins, and creates lubrification (38). In addition to this, glucosamine has been
considered an additional alternative due to its inhibition properties in cartilage decomposition and
promotion of proteoglycan synthesis. This has been considered to be a safe option in higher dosage
or in combination with hyaluronic acid (39). The most common plants which are being
demonstrated efficacious in the different preclinical and clinical study investigations are Tephrosia
toxic area, Euphorbia bicolor Latex Extract, Moringa oleifera, Grape Seed Extract, Purple Corn
Extract, Resveratrol, Curcumin, Cocoa, Lectins, Terpenes, etc (7).

Conclusion
In this review, we summarized the knowledge regarding the pharmacological treatments of TMD,
starting from the priority of treatment up to the recent developments and complementary
alternatives. There are different pharmacological groups of treatments that are used alone or in
combination with other modalities such as physical therapy or oral appliances. The current
pharmacological agents help to control inflammation, pain and provide improvement of the
symptoms but not a definitive cure. Despite the long history of their use, there are still difficult to
prioritize them and specify their main indications. However, anti-inflammatory drugs, NSAIDs,
and corticosteroids are frequently used followed by opioids, muscle relaxants, anticonvulsants,
antidepressants, and anxiolytics. Careful consideration should be in their dosage and length of
treatments, drug interactions due to their side effect profile of anti-inflammatory drugs, physical
dependence, and tolerance in opioids, physician monitoring with other central nervous action drugs
with other comorbidities.
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